862728-41-4

Upstream product

• 862728-40-3 4-(tert-butyl-dimethyl-silyloxy)-1-ethyl-cyclohexanecarboxylic acid ethyl ester 

Downstream Products

• 950772-80-2 trans-N-(5-methyl-2-nitrophenyl)-1-(1-ethyl-4-propoxycyclohexyl)-4-piperidinamine 
• 950772-81-3 trans-5-methyl-N-[1-(1-ethyl-4-propoxycyclohexyl)-4-piperidinyl]-1,2-benzenediamine 
• 950772-79-9 trans-1-[4-(propoxy)-1-ethylcyclohexyl]-4-piperidinamine 
• 950772-78-8 trans-1-[4-(propoxy)-1-ethylcyclohexyl]-4-piperidone 
• 950772-73-3 trans-ethyl 1-ethyl-4-(tert-butyldimethylsilyloxy)-cyclohexanecarboxylate 
• 950772-74-4 trans-ethyl 1-ethyl-4-propoxycyclohexanecarboxylate 
• 950772-75-5 trans-1-ethyl-4-propoxycyclohexanecarboxylic acid 
• 950772-76-6 trans-1-ethyl-4-propoxycyclohexyl isocyanate 
• 950772-77-7 trans-1-ethyl-4-propoxycyclohexylamine 
• 950772-72-2 trans-1-ethyl-4-hydroxy-cyclohexanecarboxylic acid ethyl ester 
• 950772-71-1 trans-ethyl 1-ethyl-4-(chloroacetoxy)cyclohexanecarboxylate 

Relevant academic research and scientific papers

BENZIMIDAZOLES WHICH HAVE ACTIVITY AT M1 RECEPTOR AND THEIR USES IN MEDICINE

Compounds of formula (I), salts and solvates are provided: formula (I), wherein Q, R and R6 are as defined in the claims. Uses of the compounds for therapy, for example in the treatment of psychotic disorders and cognitive impairment, are also disclosed.

Aminobenzoxazoles as therapeutic agents

A compound of Formula (I), wherein the substituents are as defined herein, which are useful as kinase inhibitors.